Research programme: ion channel modulators - Cadent Therapeutics/Saniona

Drug Profile

Research programme: ion channel modulators - Cadent Therapeutics/Saniona

Alternative Names: CAD-1883

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aniona
  • Developer Cadent Therapeutics; Saniona
  • Class Antiparkinsonians; Neuropsychotherapeutics; Small molecules
  • Mechanism of Action Small conductance calcium-activated potassium channel inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Ataxia; Essential tremor

Most Recent Events

  • 03 Nov 2017 Preclinical trials in Essential tremor in USA before November 2017 (Candent Therapeutics pipeline, November 2017)
  • 17 Oct 2017 Luc Therapeutics is now called Cadent Therapeutics
  • 14 Aug 2017 Cadent Therapeutics plans phase I clinical trials for Ataxia in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top